$KEY

Gile Elizabeth R. sold $500K of KEY

Gile Elizabeth R. sold 23,946 shares of KEYCORP /NEW/ (KEY) at $20.88 ($0.50M total) on 2026-06-03.

Original reporting
SEC EDGAR · Gile Elizabeth R.
Published Jun 5, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KEY
Neutral
medium confidence
Mentioned
$KEY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KEYNeutralLow
01

Why it matters

The disclosure updates the insider-trading tape for KEY, but provides no new operating/financial information or corporate action.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale alone is unlikely to reset valuation expectations.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-scheduled liquidity needs; without additional context (e.g., options exercises, other insiders’ trades), directional inference is weak.

Relevance 6/10Novelty 6/10Timing: after-hours / filing posted June 5 for a June 3 sale

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for KEYCORP (KEY).

Company-level read

Ticker impact

$KEYNeutralMedium confidence
Context

SEC Form 4 shows KEYCORP director Gile Elizabeth R. sold 23,946 shares in an open-market transaction on June 3.

Expected impact

Low likelihood of sustained price impact; any effect is likely brief unless followed by additional insider activity or new company-specific news.

Evidence & confidence

The filing is an ownership-change disclosure with no 10b5-1 plan and no accompanying fundamental catalyst; insider sales are often non-informational, so impact is typically muted.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

Minimal; no geographic or macro linkage beyond the issuer’s own stock.

Minimal; no cross-border transaction or regulatory action mentioned.

Counterpoint

Because the sale is open-market and not tied to a disclosed 10b5-1 plan, it could be interpreted as a stronger signal than routine sales—though the article provides no reason for the sale.

Key entities

  • KEYCORP /NEW/

    Subject of the Form 4 insider transaction; director sold shares on June 3, filed June 5.

  • Gile Elizabeth R.

    Director who reported an open-market sale of 23,946 shares at $20.8800 on June 3.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JPMMed

Major U.S. banks raise prime rate after Fed rate hike

Major U.S. banks, including JPMorgan, Bank of America, and others, raised their prime lending rate to 7% after the Federal Reserve's quarter-point rate hike. The move increases borrowing costs for consumers and businesses. Bank stocks fell, with BofA down 2.7%, Citi 2.4%, and JPMorgan 1%. Rate hikes may boost bank earnings but could also slow economic activity and impact credit quality.

$JPMMed

Major US banks raise prime rate after first Fed rate hike since 2023

Top U.S. banks, including JPMorgan and Bank of America, raised their prime lending rate to 7% after the Federal Reserve's first rate hike since 2023. The Fed increased rates by 0.25% and signaled further hikes, aiming to combat inflation. Bank shares fell, with JPMorgan down 1% and Goldman Sachs down 4%. Higher rates boost bank earnings but may slow economic activity and reduce loan demand.

$KEYMed

KeyCorp Raises 2026 Revenue Outlook: What's Driving It?

KeyCorp (KEY) raised its 2026 revenue outlook to 8% growth, up from 7-8%, citing strong loan growth, fee-based business momentum, and the Clearwater acquisition. Non-interest income is now expected to grow 4-5%, with adjusted non-interest income projected to increase 6-7%. The company also affirmed a 20%+ sequential rise in third-quarter investment-banking fees. KeyCorp anticipates 4-5% average loan growth and 9-11% net interest income growth for 2026, supported by solid loan demand and deposit

$KEYMedAI 8/10

FCA clears acquisition of Clearwater UK by KeyCorp

The UK Financial Conduct Authority cleared KeyCorp’s acquisition of corporate finance advisory firm Clearwater UK. KeyCorp completed the deal on 4 August 2026 and notified investors on the New York Stock Exchange. The article says Clearwater UK will use KeyCorp’s expertise for corporate finance advisory services.

$KEYMed

KeyCorp Q2 2026 Earnings Call Summary

KeyCorp’s Q2 2026 earnings call cited 3% sequential commercial loan growth, net interest margin expansion to 2.89%, and 12% growth in commercial payments fees. Management raised full-year revenue guidance to 7-8% growth and projected NIM of 3.0% to 3.05% by year-end, plus $1.3B+ in 2026 buybacks.